Health & Fitness
Health and Fitness
Health and Fitness
Wed, May 19, 2010 Cerus Appoints William "Obi" Greenman as Chief Business Officer
CONCORD, Calif.--([ BUSINESS WIRE ])--Cerus Corporation (NASDAQ:CERS) announced today that William "Obi" Greenman has been promoted to chief business officer. This position capitalizes on his demonstrated leadership in achieving business goals for INTERCEPT Blood System and guiding Cerus' corporate strategy.
"He brings a passion and depth of knowledge that we expect will continue to drive the company forward as we grow our sales in Europe, pursue new markets for INTERCEPT platelets and plasma, and advance our INTERCEPT red cell program toward European approval."
"Obi's contributions to the development, commercialization, marketing and sales of the INTERCEPT Blood System have been a critical element in Cerus' success," said Claes Glassell, Cerus' president and chief executive officer. "He brings a passion and depth of knowledge that we expect will continue to drive the company forward as we grow our sales in Europe, pursue new markets for INTERCEPT platelets and plasma, and advance our INTERCEPT red cell program toward European approval."
Mr. Greenmanhas been Cerus' senior vice president, business development and marketing since 2008. From 2006 to 2008, he held the position of president, Cerus Europe, and prior to that, after returning to the company from a brief time in the venture capital business, he served as vice president, business development. Prior to joining Cerus in 1995 as director of business development, Mr. Greenman worked in various marketing and business development positions in Baxtera™s Biotech Division from 1991 to 1995.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action allows INTERCEPT treatment to inactivate both established transfusion threats, such as hepatitis, HIV, West Nile virus and bacteria, as well as emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. Visit [ http://www.cerus.com ] for more information.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the scope and rate of sales of the INTERCEPT Blood System, the pursuit of new markets for INTERCEPT platelets and plasma and European approval of the INTERCEPT red cell program. Words such as aexpecta and similar expressions are intended to identify forward-looking statements.These forward-looking statements are based upon the companya™s current expectations.Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with commercial adoption of INTERCEPT pathogen inactivation technology, regulatory approvals, as well as other risks detailed in the Cerus' filings with, the Securities and Exchange Commission (SEC), including in Cerus' quarterly report on Form 10-Q for the quarter ended March 31, 2010, filed with the SEC on May 12, 2010. No pathogen inactivation system has been shown to inactivate all pathogens.You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
